Increased Cytoplasmic Localization of p27kip1 and Its Modulation of RhoA Activity during Progression of Chronic Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Roy, Anita ^a   Lahiry, Lakshmishri ^a   Banerjee, Debasis ^b   Ghosh, Malay ^c   Banerjee, Subrata ^a  

^a SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

^b Ramkrishna Mission Seva Pratisthan ^*  (India)

^c NRS MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMATINIB; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; BLAST TRANSFORMATION; CANCER GROWTH; CD34 SELECTION; CELL CYCLE PHASE; CELL STRAIN K 562; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STEM CELL; WNT SIGNALING PATHWAY;

ANTHRACENES; ANTIGENS, CD34; APOPTOSIS; BLAST CRISIS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GUANOSINE TRIPHOSPHATE; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC-PHASE; LYMPHOCYTES; MAP KINASE KINASE 4; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84885056560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076527     Document Type: Article

References (54)

1. Deininger MW, Goldman JM, Melo JV, (2000) The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356. PubMed: 11071626.
2. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, et al. (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121: 396-409. doi:10.1172/JCI35721. PubMed: 21157039.
3. O'Hare T, Eide CA, Deininger MW, (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249. doi:10.1182/blood-2007-03-066936. PubMed: 17496200.
4. Cortez D, Reuther G, Pendergast AM, (1997) The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342. doi:10.1038/sj.onc.1201400. PubMed: 9393877.
5. Jena N, Deng M, Sicinska E, Sicinski P, Daley GQ, (2002) Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res 62: 535-541. PubMed: 11809706.
6. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ, (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038-2044. PubMed: 8161775.
7. Cortez D, Kadlec L, Pendergast AM, (1995) Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15: 5531-5541. PubMed: 7565705.
8. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI, (1994) A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 91: 5291-5295. doi:10.1073/pnas.91.12.5291.
9. Hengst L, Reed SI, (1996) Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-1864. doi:10.1126/science.271.5257.1861. PubMed: 8596954.
10. Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, et al. (2000) Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96: 1933-1939. PubMed: 10961897.
11. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, et al. (2005) BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65: 3264-3272. PubMed: 15833859.
12. Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, et al. (2008) Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 112: 1960-1970. doi:10.1182/blood-2007-09-113860.
13. Chu S, McDonald T, Bhatia R, (2010) Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors. Leukemia 24: 779-787. doi:10.1038/leu.2010.24.
14. Borriello A, Caldarelli I, Bencivenga D, Cucciolla V, Oliva A, et al. (2011) p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis 32: 10-18. doi:10.1093/carcin/bgq211. PubMed: 20952511.
15. Sengupta A, Banerjee D, Chandra S, Banerjee S, (2006) Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector. J Gene Med 8: 1251-1261. doi:10.1002/jgm.959. PubMed: 16952195.
16. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF, (2003) Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 23: 216-228.
17. Wander SA, Zhao D, Slingerland JM, (2011) p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 17: 12-18. doi:10.1158/1078-0432.CCR-10-0752.
18. Denicourt C, Saenz CC, Datnow B, Cui XS, Dowdy SF, (2007) Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res 67: 9238-9243. doi:10.1158/0008-5472.CAN-07-1375.
19. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM, (2004) p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18: 862-876. doi:10.1101/gad.1185504. PubMed: 15078817.
20. Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, et al. (2009) RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A 106: 9268-9273. doi:10.1073/pnas.0805057106. PubMed: 19470470.
21. Sengupta A, Banerjee S, (2007) Pleiotropic p27(Kip1), BCR-ABL and leukemic stem cell: the trio in concert. Leukemia 21: 2559-2561. doi:10.1038/sj.leu.2404842.
22. Takaishi K, Kikuchi A, Kuroda S, Kotani K, Sasaki T, et al. (1993) Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol 13: 72-79.
23. Kishi K, Sasaki T, Kuroda S, Itoh T, Takai Y, (1993) Regulation of cytoplasmic division of Xenopus embryo by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI). J Cell Biol 120: 1187-1195. doi:10.1083/jcb.120.5.1187.
24. Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K, et al. (1992) Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem 267: 8719-8722.
25. Yoshioka K, Nakamori S, Itoh K, (1999) Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 59: 2004-2010.
26. Zhang S, Tang Q, Xu F, Xue Y, Zhen Z, et al. (2009) RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors. Mol Cancer Res 7: 570-580. doi:10.1158/1541-7786.MCR-08-0248.
27. Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, et al. (2007) Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21: 949-955.
28. Roy A, Basak NP, Banerjee S, (2012) Notch1 intracellular domain increases cytoplasmic EZH2 levels during early megakaryopoiesis. Cell Death. Drosophila Inf Serv 3: e380.
29. Bokoch GM, Bohl BP, Chuang TH, (1994) Guanine nucleotide exchange regulates membrane translocation of Rac/Rho GTP-binding proteins. J Biol Chem 269: 31674-31679.
30. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, et al. (2001) p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 20: 6672-6682. doi:10.1093/emboj/20.23.6672. PubMed: 11726503.
31. Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, et al. (2005) The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. Blood 105: 775-783. doi:10.1182/blood-2004-04-1242. PubMed: 15353483.
32. Parada Y, Banerji L, Glassford J, Lea NC, Collado M, et al. (2001) BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem 276: 23572-23580. doi:10.1074/jbc.M101885200.
33. Gomez-Casares MT, Garcia-Alegria E, Lopez-Jorge CE, Ferrandiz N, Blanco R, et al. (2013) MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). Oncogene 32: 2239-2246. doi:10.1038/onc.2012.246. PubMed: 22710719.
34. Zhao RC, Jiang Y, Verfaillie CM, (2001) A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 97: 2406-2412. doi:10.1182/blood.V97.8.2406.
35. Daubon T, Chasseriau J, El Ali A, Rivet J, Kitzis A, et al. (2008) Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs. Oncogene 27: 2673-2685. doi:10.1038/sj.onc.1210933. PubMed: 18059343.
36. Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, et al. (2008) The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 27: 2064-2071. doi:10.1038/sj.onc.1210841. PubMed: 17922031.
37. Unwin RD, Sternberg DW, Lu Y, Pierce A, Gilliland DG, et al. (2005) Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. J Biol Chem 280: 6316-6326. doi:10.1074/jbc.M410598200. PubMed: 15569670.
38. Etienne-Manneville S, Hall A, (2002) Rho GTPases in cell biology. Nature 420: 629-635. doi:10.1038/nature01148. PubMed: 12478284.
39. Kurokawa K, Matsuda M, (2005) Localized RhoA activation as a requirement for the induction of membrane ruffling. Mol Cell Biol 16: 4294-4303. doi:10.1091/mbc.E04-12-1076. PubMed: 15987744.
40. Michaelson D, Silletti J, Murphy G, D'Eustachio P, Rush M, et al. (2001) Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J Cell Biol 152: 111-126. doi:10.1083/jcb.152.1.111. PubMed: 11149925.
41. Street CA, Bryan BA, (2011) Rho kinase proteins--pleiotropic modulators of cell survival and apoptosis. Anticancer Res 31: 3645-3657. PubMed: 22110183.
42. Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, et al. (2004) Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 103: 656-663. doi:10.1182/blood-2003-07-2559. PubMed: 14563636.
43. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL, (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 92: 11746-11750. doi:10.1073/pnas.92.25.11746. PubMed: 8524841.
44. Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, et al. (1998) Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood 92: 2450-2460. PubMed: 9746785.
45. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, et al. (2004) The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 14: 29-41. doi:10.1016/S1097-2765(04)00153-4. PubMed: 15068801.
46. Alberts AS, Treisman R, (1998) Activation of RhoA and SAPK/JNK signalling pathways by the RhoA-specific exchange factor mNET1. EMBO J 17: 4075-4085. doi:10.1093/emboj/17.14.4075.
47. Fromigué O, Hamidouche Z, Marie PJ, (2008) Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283: 30549-30556. doi:10.1074/jbc.M801436200. PubMed: 18757369.
48. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, et al. (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65: 8912-8919. doi:10.1158/0008-5472.CAN-05-0076. PubMed: 16204063.
49. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ, (2002) Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32: 201-205. doi:10.1038/ng946. PubMed: 12161751.
50. Zhu S, Korzh V, Gong Z, Low BC, (2008) RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek/Erk pathway. Oncogene 27: 1580-1589. doi:10.1038/sj.onc.1210790. PubMed: 17873909.
51. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, et al. (2002) Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277: 15309-15316. doi:10.1074/jbc.M201253200. PubMed: 11839765.
52. Del Re DP, Miyamoto S, Brown JH, (2007) RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem 282: 8069-8078. doi:10.1074/jbc.M604298200. PubMed: 17234627.
53. Miñambres R, Guasch RM, Perez-Aragó A, Guerri C, (2006) The RhoA/ROCK-I/MLC pathway is involved in the ethanol-induced apoptosis by anoikis in astrocytes. J Cell Sci 119: 271-282. doi:10.1242/jcs.02723. PubMed: 16390872.
54. Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, et al. (2003) Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells 21: 315-321. doi:10.1634/stemcells.21-3-315. PubMed: 12743326.